Phase 1/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
Latest Information Update: 21 Jul 2025
At a glance
- Drugs NTS 071 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms NTS071
- Sponsors NUTSHELL Therapeutics
Most Recent Events
- 11 Jul 2025 Status changed from planning to not yet recruiting.
- 27 Jun 2025 New trial record
- 04 May 2025 According to the Nutshell Therapeutics media release, company received IND clearance from the FDA to initiate Phase 1 clinical trial and trial initiation anticipated in second half of 2025.